Kyntra Bio (KYNB) news

Kyntra Bio, Inc.: Maxim Group initiates coverage with buy rating; target price $35

Maxim Group, a well-established investment bank, has initiated coverage of Kyntra Bio, Inc. (NASDAQ: KYNB) with a "Buy" rating and a target price of $35 per share. This move comes amid a period of strategic repositioning for the biopharmaceutical company, which rebranded from FibroGen in early 2026…

Kyntra Bio appoints Andrew E. Singer, MBA to its board of directors

Kyntra Bio, - Pro forma cash, equivalents, investments, receivables $53.10 mln as of June 30, 2026

Kyntra Bio reported pro forma cash, cash equivalents, investments, and receivables of $53.10 million as of June 30, 2026, according to the latest available financial data [1]. This figure reflects the company’s liquidity position following any recent financing activities or business combinations…

Kyntra Bio, - Cash runway expected into fourth quarter of 2027

Kyntra Bio has reported that its current cash runway is expected to extend through the fourth quarter of 2027, based on its existing financial resources and operational spending plans. This projection is outlined in the company’s most recent financial disclosure, which indicates a continued focus…

Kyntra Bio, - Reduces royalty financing payment cap to $65 mln from $125 mln

Kyntra Bio has announced a reduction in the maximum payment cap for its royalty financing agreement from $125 million to $65 million, according to a recent filing. This adjustment reflects the company’s ongoing strategy to manage financial obligations while maintaining flexibility in capital…